Amyloidosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Amyloidosis Pipeline Drugs Market Overview
Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of an abnormal protein called the light chain and its subsequent deposition in the body. It may also occur because of dialysis. Symptoms include fatigue, chest pain, swelling, and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.
The Amyloidosis drugs in development market research report provide comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.
Key Targets in the Amyloidosis Pipeline Products Market
The key targets in the Amyloidosis pipeline products market are Transthyretin, Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide, Alpha Synuclein, Amyloid Beta A4 Protein, Interleukin 1 Beta, Microtubule Associated Protein Tau, B Cell Lymphoma 2, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, 20s Proteasome, and others.
Amyloidosis Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Amyloidosis Pipeline Products Market
The key mechanisms of action in the Amyloidosis pipeline products market are Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and others.
Amyloidosis Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Amyloidosis Pipeline Products Market
The key routes of administration in the Amyloidosis pipeline products market are intravenous, subcutaneous, oral, parenteral, and topical.
Amyloidosis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Amyloidosis Pipeline Products Market
The key molecule types in the Amyloidosis pipeline products market are small molecule, monoclonal antibody, fusion protein, antisense RNAi oligonucleotide, gene therapy, Antisense Oligonucleotide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, recombinant peptide, antibody, and others.
Amyloidosis Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Amyloidosis Pipeline Products Market
Some of the major companies in the Amyloidosis pipeline products market are Alnylam Pharmaceuticals Inc, Akcea Therapeutics Inc, Attralus Inc, Johnson & Johnson, Alexion Pharmaceuticals Inc, Autotac Bio Inc, BridgeBio Pharma Inc, BSIM Therapeutics SA, Millennium Pharmaceuticals Inc, and Proclara Biosciences Inc.
Amyloidosis Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
| Key targets | Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and Others |
| Key mechanism of action | Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and others |
| Key routes of administration | Intravenous, Subcutaneous, Oral, Parenteral, and Topical |
| Key molecule type | Small Molecule, Monoclonal Antibody, Fusion Protein, Antisense RNAi Oligonucleotide, Gene Therapy, Antisense Oligonucleotide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Recombinant Peptide, Antibody, and Others |
| Major companies | Alnylam Pharmaceuticals Inc, Akcea Therapeutics Inc, Attralus Inc, Johnson & Johnson, Alexion Pharmaceuticals Inc, Autotac Bio Inc, BridgeBio Pharma Inc, BSIM Therapeutics SA, Millennium Pharmaceuticals Inc, and Proclara Biosciences Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key targets in the Amyloidosis pipeline products market are Transthyretin, Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide, Alpha Synuclein, Amyloid Beta A4 Protein, Interleukin 1 Beta, Microtubule Associated Protein Tau, B Cell Lymphoma 2, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, 20s Proteasome, and others.
The key mechanisms of action in the Amyloidosis pipeline products market are Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and others.
The key routes of administration in the Amyloidosis pipeline products market are intravenous, subcutaneous, oral, parenteral, and topical.
The key molecule types in the Amyloidosis pipeline products market are small molecule, monoclonal antibody, fusion protein, antisense RNAi oligonucleotide, gene therapy, antisense oligonucleotide, gene-modified cell therapy, monoclonal antibody conjugated, recombinant peptide, antibody, and others.
Some of the major companies in the Amyloidosis pipeline products market are Alnylam Pharmaceuticals Inc, Akcea Therapeutics Inc, Attralus Inc, Johnson & Johnson, Alexion Pharmaceuticals Inc, Autotac Bio Inc, BridgeBio Pharma Inc, BSIM Therapeutics SA, Millennium Pharmaceuticals Inc, and Proclara Biosciences Inc.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Metabolic Disorders reports